Skip to main content
An official website of the United States government
Email

Commercialization Readiness Pilot Program

Notice Number: PAR-23-129

Receipt dates: September 5, 2024; January 5, 2025; April 5, 2025
Expiration date: April 6, 2025

 

The Funding Opportunity Announcement aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a FDA submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the small business concern is expected to maintain oversight and management of the R&D throughout the award. Clinical trials not accepted under this FOA.

 

Award budget: 

Total funding support may not exceed $250,000 in total costs (direct costs, indirect costs, fee).

Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the hard caps listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. The scope of the proposed project should determine the project period. The maximum project period allowed is 2 years.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Commercialization Readiness Pilot Program was originally published by the National Cancer Institute.”

Email